CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CARABELA-NF1 project aims to improve treatment strategies for HR+/HER2- breast cancer patients by identifying genetic markers of drug resistance. It combines clinical trial data with genomic profiling to develop predictive signatures and test new therapeutic approaches, addressing the urgent need for effective neoa…
HR+/HER2- breast cancer (BC) patients often show limited response to current neoadjuvant chemotherapy, highlighting the critical need for alternative therapeutics strategies.
The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) is the standard of care in adjuvant treatment for HR+/HER2- BC, with the potential for significantly improved outcomes in the neoadjuvant setting.
However, drug resistance remains a significant challenge, with a critical need for early-stage biomarke…
FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
